Tadasu Matsuo, head of alternative investments at Japan Post Insurance (JPI), has joined HarbourVest Partners as a managing director where he will co-lead Japan coverage alongside Tatsuya Kubo.
Matsuo (pictured) was recruited by JPI in September 2016 to launch the firm’s alternative investment program. He previously spent 14 years at Daido Life Insurance as general manager for alternative investment...
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.